Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Medical Genetics, |
RCV000005812 | SCV001976880 | uncertain significance | Macular degeneration, age-related, 3 | 2021-10-06 | criteria provided, single submitter | clinical testing | PM2, PP3, PP5 |
Labcorp Genetics |
RCV001851679 | SCV002154611 | uncertain significance | not provided | 2023-08-17 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change does not substantially affect FBLN5 function (PMID: 20007835). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 5478). This missense change has been observed in individual(s) with age-related macular degeneration (PMID: 15269314). This variant is present in population databases (rs121434300, gnomAD 0.005%). This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 71 of the FBLN5 protein (p.Arg71Gln). |
OMIM | RCV000005812 | SCV000025994 | pathogenic | Macular degeneration, age-related, 3 | 2004-07-22 | no assertion criteria provided | literature only | |
Inherited Neuropathy Consortium Ii, |
RCV003447070 | SCV004174403 | uncertain significance | Age-related macular degeneration | 2016-01-06 | no assertion criteria provided | literature only |